Adverse event management as a pathway to optimal outcomes in head and neck squamous cell carcinoma patients: A clinical case
- Authors: Sanikovich V.D.1, Sekacheva M.I.1, Orlova E.V.1, Gabrielian G.A.1, Boroda A.M.1, Agakina J.S.1,2, Reshetov I.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological Agency
- Issue: Vol 26, No 6 (2024): Персонализированная онкология в реальной клинической практике
- Pages: 386-395
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/263223
- DOI: https://doi.org/10.26442/20751753.2024.6.202912
- ID: 263223
Cite item
Full Text
Abstract
Squamous cell carcinoma of the head and neck is the sixth most common cancer worldwide. However, malignant tumors of the middle ear are extremely rare. Squamous cell carcinoma is the most common histologic type of tumor in this area, accounting for more than 50% of cases. Complex anatomical and topographic features of the inner ear and inapparent clinical symptoms result in delayed diagnosis of this disease. A case of a patient with highly differentiated middle ear squamous cell carcinoma is presented. The patient received complex treatment, including drug antitumor therapy according to the TPEx protocol: docetaxel + cisplatin + cetuximab. Being highly effective, this protocol requires a multidisciplinary approach in order to ensure maximum safety of therapy. The case illustrates the classic “portrait” of a patient with recurrent or metastatic squamous cell carcinoma of the head and neck and also provides a comprehensive description of the spectrum of adverse events faced by such patients and their oncologists. Based on this clinical case, the features of management of such adverse events are analyzed.
Full Text
##article.viewOnOriginalSite##About the authors
Varvara D. Sanikovich
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: sanikovich_v_d@staff.sechenov.ru
ORCID iD: 0000-0002-4840-4106
Res. Assist.
Russian Federation, MoscowMarina I. Sekacheva
Sechenov First Moscow State Medical University (Sechenov University)
Email: sekacheva_m_i@staff.sechenov.ru
ORCID iD: 0000-0003-0015-7094
D. Sci. (Med.), Prof.
Russian Federation, MoscowEkaterina V. Orlova
Sechenov First Moscow State Medical University (Sechenov University)
Email: orlovaderm@yandex.ru
ORCID iD: 0000-0002-1684-8781
Cand. Sci. (Med.)
Russian Federation, MoscowGaiane A. Gabrielian
Sechenov First Moscow State Medical University (Sechenov University)
Email: gaya0412@mail.ru
ORCID iD: 0000-0002-9238-4165
Graduate Student
Russian Federation, MoscowAlexander M. Boroda
Sechenov First Moscow State Medical University (Sechenov University)
Email: boroda_a_m@staff.sechenov.ru
ORCID iD: 0000-0002-4196-6042
Res. Officer
Russian Federation, MoscowJuliya S. Agakina
Sechenov First Moscow State Medical University (Sechenov University); Federal Research and Clinical Center of specialized types of health care and medical technology of the Federal Medical and Biological Agency
Email: agakina_yu_s@staff.sechenov.ru
ORCID iD: 0000-0002-3556-2703
Department Head; Аssistant
Russian Federation, Moscow; MoscowIgor V. Reshetov
Sechenov First Moscow State Medical University (Sechenov University)
Email: ivreshetov@mail.ru
ORCID iD: 0000-0002-0909-6278
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowReferences
- Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2024. Available at: https://gco.iarc.who.int/today. Accessed: 15.05.2024.
- Srivani N, Joyce TM. Clinicopathology of Middle Ear Tumours: A Retrospective Study from a Tertiary Care Hospital, Hyderabad, India. J Clin Diagn Res. 2022;16(7):EC27-31. doi: 10.7860/JCDR/2022/52936/16646
- Gurgel RK, Karnell LH, Hansen MR. Middle ear cancer: a population-based study. Laryngoscope. 2009;119(10):1913-7. doi: 10.1002/lary.20202
- Hu XD, Wu TT, Zhou SH. Squamous cell carcinoma of the middle ear: report of three cases. Int J Clin Exp Med. 2015;8(2):2979-84.
- Attakkil A, Thorawade V, Jagade M, et al. Squamous Cell Carcinoma of the Middle Ear Mimicking CSOM with Intracranial Complications: A Diagnostic Dilemma. International Journal of Otolaryngology and Head & Neck Surgery. 2014;3:376-81. doi: 10.4236/ijohns.2014.36067
- Pontes F, Garcia AR, Domingues I, et al. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. Cancer Treat Res Commun. 2021;27:100375. doi: 10.1016/j.ctarc.2021.100375
- Burtness B, Harrington KJ, Greil R, et al.; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28. doi: 10.1016/S0140-6736(19)32591-7. Erratum in: Lancet. 2020;395(10220):272. doi: 10.1016/S0140-6736(20)30116-1. Erratum in: Lancet. 2020;395(10224):564. doi: 10.1016/S0140-6736(20)30254-3. Erratum in: Lancet. 2021;397(10291):2252. doi: 10.1016/S0140-6736(21)01119-3
- Rettig EM, D'Souza G, Thompson CB, et al. Health-related quality of life before and after head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage. Cancer. 2016;122(12):1861-70. doi: 10.1002/cncr.30005
- Quinten C, Coens C, Mauer M, et al.; EORTC Clinical Groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865-71. doi: 10.1016/S1470-2045(09)70200-1
- Rogers SN, Waylen AE, Thomas S, et al. Quality of life, cognitive, physical and emotional function at diagnosis predicts head and neck cancer survival: analysis of cases from the Head and Neck 5000 study. Eur Arch Otorhinolaryngol. 2020;277(5):1515-23. doi: 10.1007/s00405-020-05850-x
- Head & Neck Cancers: Essentials for Clinicians. Edited by L Licitra, MV Karamouzis. 2017.
- Lop J, Venegas MDP, Pujol A, et al. Causes of long-term mortality in patients with head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol. 2022;279(7):3657-64. doi: 10.1007/s00405-021-07211-8
- Zapata I, Alvarez M, Hidalgo R, et al. Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy. BMC Cancer. 2019;19(1):1241. doi: 10.1186/s12885-019-6427-1
- Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., и др. Практические рекомендации по лекарственному лечению опухолей головы и шеи. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023;13(#3s2):100-19 [Bolotina LV, Vladimirova LIu, Den'gina NV, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu opukholei golovy i shei. Prakticheskie Rekomendatsii RUSSCO, Chast' 1. Zlokachestvennye Opukholi. 2023;13(#3s2):100-19 (in Russian)]. doi: 10.18027/2224-5057-2023-13-3s2-1-100-119
- Machiels JP, René Leemans C, Golusinski W, et al.; EHNS Executive Board; ESMO Guidelines Committee; ESTRO Executive Board. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462-75. doi: 10.1016/j.annonc.2020.07.011
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Head and Neck Cancers. Version 4.2024 – May 1, 2024.
- Black MD, Yoo J, Fung K, et al. Personalized Treatment of Recurrent, Metastatic Head and Neck Cancer Guided by Patient-Derived Xenograft Models. Cureus. 2024;16(2):e53645. doi: 10.7759/cureus.53645
- Guigay J, Aupérin A, Fayette J, et al.; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-75. doi: 10.1016/S1470-2045(20)30755-5
- Bonomo P, Paderno A, Mattavelli D, et al. Quality Assessment in Supportive Care in Head and Neck Cancer. Front Oncol. 2019;9:926. doi: 10.3389/fonc.2019.00926
- Королева И.А., Болотина Л.В., Гладков О.А., и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(#3s2):108-31 [Koroleva IA, Bolotina LV, Gladkov OA, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniiu dermatologicheskikh reaktsii u patsientov, poluchaiushchikh protivoopukholevuiu lekarstvennuiu terapiiu. Prakticheskie Rekomendatsii RUSSCO, Chast' 2. Zlokachestvennye Opukholi. 2023;13(#3s2):108-31 (in Russian)].
- Doxycycline Side Effects from Drugs.com; 1996–2018. Available at: https://www.drugs.com/sfx/doxycycline-side-effects.html#professional-info. Accessed: 15.05.2024.
- Boland JW, Allgar V, Boland EG, et al. The relationship between pain, analgesics and survival in patients with advanced cancer; a secondary data analysis of the international European palliative care Cancer symptom study. Eur J Clin Pharmacol. 2020;76(3):393-402. doi: 10.1007/s00228-019-02801-2
- Fallon M, Giusti R, Aielli F, et al.; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv166-91. doi: 10.1093/annonc/mdy152
- Katopodis P, Karteris E, Katopodis KP. Pathophysiology of Drug-Induced Hypomagnesaemia. Drug Saf. 2020;43(9):867-80. doi: 10.1007/s40264-020-00947-y
- Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649-52. doi: 10.1681/ASN.2007070792
- Verzicco I, Regolisti G, Quaini F, et al. Electrolyte Disorders Induced by Antineoplastic Drugs. Front Oncol. 2020;10:779. doi: 10.3389/fonc.2020.00779
- Остроумова О.Д., Кочетков А.И., Клепикова М.В. Лекарственно-индуцированный дефицит электролитов. Часть 2. Лекарственно-индуцированная гипомагниемия. РМЖ. 2020;12:36-48 [Ostroumova OD, Kochetkov AI, Klepikova MV. Drug-induced electrolyte disorder. Part 2. Drug-induced hypomagnesemia. RMJ. 2020;12:36-48 (in Russian)].
- Workeneh BT, Uppal NN, Jhaveri KD, Rondon-Berrios H. Hypomagnesemia in the Cancer Patient. Kidney360. 2020;2(1):154-66. doi: 10.34067/KID.0005622020
- Сакаева Д.Д., Борисов К.Е., Булавина И.С., и др. Практические рекомендации по диагностике и лечению фебрильной нейтропении. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(#3s2):62-71 [Sakaeva DD, Borisov KE, Bulavina IS, et al. Prakticheskie rekomendatsii po diagnostike i lecheniiu febril'noĭ neĭtropenii. Prakticheskie Rekomendatsii RUSSCO, Chast' 2. Zlokachestvennye Opukholi. 2023;13(#3s2):62-71 (in Russian)].
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hematopoietic Growth Factors. Version 3.2024 – January 30, 2024.
- Орлова Р.В., Жабина А.С., Иванова А.К., и др. Практические рекомендации по лечению инфузионных реакций при проведении противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(#3s2):261-81 [Orlova RV, Zhabina AS, Ivanova AK, et al. Prakticheskie rekomendatsii po lecheniiu infuzionnykh reaktsii pri provedenii protivoopukholevoi lekarstvennoi terapii. Prakticheskie Rekomendatsii RUSSCO, Chast' 2. Zlokachestvennye Opukholi. 2023;13(#3s2):261-81 (in Russian)].
- Полонская А.С., Шатохина Е.А., Круглова Л.С. Дерматологические нежелательные явления ингибиторов рецептора эпидермального фактора роста: современный взгляд на междисциплинарную проблему. Опухоли головы и шеи. 2021;11(4):97-109 [Polonskaia AS, Shatokhina EA, Kruglova LS. Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem. Head and Neck Tumor. 2021;11(4):97-109 (in Russian)]. doi: 10.17650/2222-1468-2021-11-4-97-109
- Bozzetti F, Cotogni P. Nutritional Issues in Head and Neck Cancer Patients. Healthcare (Basel). 2020;8(2):102. doi: 10.3390/healthcare8020102
- Kristensen MB, Isenring E, Brown B. Nutrition and swallowing therapy strategies for patients with head and neck cancer. Nutrition. 2020;69:110548. doi: 10.1016/j.nut.2019.06.028
- Сытов А.В., Зузов С.А., Кукош М.Ю., и др. Практические рекомендации по нутритивной поддержке онкологических больных. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(#3s2):131-41 [Sytov AV, Zuzov SA, Kukosh MIu, et al. Prakticheskie rekomendatsii po nutritivnoi podderzhke onkologicheskikh bol'nykh. Prakticheskie Rekomendatsii RUSSCO, Chast' 2. Zlokachestvennye Opukholi. 2023;13(#3s2):131-41 (in Russian)].
- Martinovic D, Tokic D, Puizina Mladinic E, et al. Nutritional Management of Patients with Head and Neck Cancer-A Comprehensive Review. Nutrients. 2023;15(8):1864. doi: 10.3390/nu15081864